<DOC>
	<DOCNO>NCT00820768</DOCNO>
	<brief_summary>To determine MTD DLT ABI-010 give weekly every three week follow one week rest ( Cycle 1 ) . Determine MLD DLT combination ABI-007 ; characterize toxicity ABI-010 alone combination ABI-007 .</brief_summary>
	<brief_title>A Trial ABI-010 &amp; ABI-007 Patients With Advanced Non-Hematologic Malignancies</brief_title>
	<detailed_description />
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<criteria>Each subject must meet follow criterion enrol study : 1 . Pathologically confirm advanced solid tumor malignancy . 2 . Measurable evaluable advanced solid tumor . 3 . Patients advance solid tumor malignancy fail standard therapy standard therapy exists . Patients fail standard therapy receive 3 prior chemotherapy regimen . 4 . Patients must recover least 3 week prior treatment regimen residual toxicity &gt; Grade 2 ( exception peripheral neuropathy must improve ≤ Grade 1 ) . 5 . Patient full recovery reversible side effect prior chemotherapy . 6 . Patient full recovery least 4 week since major surgery . 7 . ECOG performance status 02 . 8 . Age ≥18 year . 9 . Patient must follow blood count Baseline : WBC ≥ 3.0 x 10 cells/L . ANC ≥ 1.5 x 10 cells/L . Platelets ≥ 100 x 10 cells/L . Hgb ≥ 9grams/dL . 10 . Patient must follow blood chemistry level Baseline : AST ( SGOT ) , ALT ( SGPT ) ≤ 1.5x upper limit normal range ( ULN ) ; Total Bilirubin ≤ ULN ; Alkaline phosphatase ≤ 2.5x ULN ( unless bone metastasis present absence liver metastasis ; Creatinine ≤ 1.5 mg/dL 11 . Peripheral neuropathy Grade ≤ 1 NCI CTCAE V3.0 . 12 . Female childbearing potential negative serum pregnancy test within 72 hour prior first dose study drug . 13 . Males female reproductive potential must agree utilize contraception consider adequate appropriate investigator ( include one barrier method ) duration study 2 month end study . 14 . Life expectancy ≥ 3 month . 15 . Informed consent document obtain . 16 . If obese , patient must treat dos calculate use his/her actual BSA ( physician must comfortable treat full BSA dose regardless BSA ) . Subjects meet follow criterion exclude study . 1 . Concurrent therapy ( chemotherapy , hormonal therapy , kinase inhibitor , immunotherapy , etc ) advance solid tumor . 2 . Patients receive know CYP450 3A4 inhibitor . 3 . Bisphosphonate therapy allow , however , patient stable current bisphosphonate , change , start stop treatment within 4 week prior enrollment . 4 . Patients know brain metastasis leptomeningeal tumor involvement exclude clinical trial . 5 . Uncontrolled intercurrent illness include , limited , serious ongoing active infection , symptomatic congestive heart failure , unstable angina pectoris , cardiac arrhythmia , psychiatric illness/ social situation would limit compliance study . 6 . Patients significant cardiovascular disease include congestive heart failure ( New York Heart Association Class III IV ) , active angina pectoris recent myocardial infarction ( within last 6 month ) . 7 . History malignancy within last 5 year would affect diagnosis assessment advance solid tumor exclude nonmelanomatous skin cancer cervical carcinoma . 8 . Patients receive investigational drug within previous 3 week . 9 . Patient currently enrol clinical study investigational procedure perform investigational therapy administer . A patient may enroll clinical trial participate study . 10 . Pregnant nursing woman . 11 . Patients history allergy hypersensitivity study drug excipients . 12 . Patients mark baseline prolongation QT/QTc interval ( &gt; 450 millisecond ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2011</verification_date>
</DOC>